China Post Securities: Rated "Buy" for Aurite, Aurin successfully approved, product structure further perfected.

According to the research report of China Post Securities, Aortech's preparation new product Oshotong officially obtained the drug registration certificate issued by the National Medical Products Administration in November 2025. This is the second preparation product approved by the company in the field of women's health, following the approval of Aoxintong dienogest tablets in 2023. The company's national distribution network is constantly improving, continuously strengthening the expert system construction, promoting the entrance of preparations. In the first half of 2025, Aoxintong added 1754 entrants, achieving sales revenue of 95.6852 million yuan. The smooth approval of Oshotong this time is expected to bring more incremental business to the preparation industry. The company is proactively developing the technology and production capacity of new products such as peptides and oligonucleotides. Since 2025, the sales of new products have grown rapidly. The company is a high-quality specialty raw material supplier, leading domestically in the field of peptide and oligonucleotide raw materials, first coverage, and a "buy" rating is given.